ALMS Bathi resik saben saham sajrone 12 wulan pungkasan Alumis

Alumis Inc. (ALMS) develops IT platforms and anti-inflammatory drugs, diversifying its research across various diseases. High barriers to entry and patent protection for its molecules shield the business from new competitors. The company's EPS TTM trend demonstrates a balance between actual earnings and market value, where the value of -3.82 reflects the current figure. Currently, the biotech firm is actively deploying its IPO capital to conduct costly clinical trials.

This indicator measures the aggregate net income distributed per share over a rolling year, allowing for an assessment of the business's actual value generation efficiency. By analyzing the TTM net income per share on the GURU.Markets platform, an investor separates market noise from the operational resilience of Alumis Inc. (ALMS), weighing financial results against the risks of FDA regulatory restrictions for the TYK2 drug class.